Two oral incretin-based therapies — oral semaglutide (a peptide GLP-1 receptor agonist) and orforglipron (a small-molecule biased GLP-1 receptor agonist) — have received FDA approval for obesity treatment, with phase 3 trials demonstrating weight loss exceeding 10% body weight. Oral semaglutide carries an additional indication for secondary cardiovascular risk reduction. Both agents maintain adverse-event profiles consistent with the broader GLP-1 drug class, though first-generation small-molecule incretin therapies have raised concerns around drug-induced liver injury — a signal demanding monitoring as the field matures.
The arrival of effective oral GLP-1 agonists represents a genuinely meaningful inflection point in obesity pharmacotherapy. Injectable semaglutide (Ozempic, Wegovy) transformed the field but created substantial barriers: needle aversion, cold-chain logistics, and cost. Oral bioavailability has historically been the Achilles heel of peptide drugs, making the absorption technologies enabling these formulations a legitimate engineering breakthrough. The >10% weight loss threshold matters clinically — it correlates with meaningful reductions in cardiometabolic risk factors. That said, this review is a narrative synthesis, not a new trial, so it inherits the limitations of the underlying phase 3 data: relatively short follow-up windows and questions about long-term weight maintenance. The liver-injury signal from earlier small-molecule candidates is a real caution flag that differentiates drug classes within this category. For adults struggling with obesity who cannot or will not self-inject, these approvals meaningfully expand practical options — making this development confirmatory in mechanism but genuinely paradigm-shifting in accessibility.